B+
Bull case
20%
Probability
Target price
$1.30
-88.3% vs current
PSNL
PersonalisDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$0.90
-91.9% vs current
B-
Bear case
25%
Probability
Target price
$0.45
-96.0% vs current
AI sentiment snapshot
Latest data as of 2025-11-26
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market tone is cautious-to-bearish driven by cash-burn concerns and low trading liquidity; some investor interest remains around long-term commercial adoption narratives [#PR-2025-06-10], but near-term sentiment is sensitive to funding news [#10Qp34]. Analysts/coverage are limited, increasing information asymmetry and volatility [#EDGAR-10-K].
RankAlpha Sentiment AI - 2025-11-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2025-12-15eventQuarterly earnings release (FYQ4/FY2025)High impact
Earnings release and conference call could move shares via revenue guidance, cash runway commentary, and any change to clinical/commercial uptake; last reported trends showed slim revenues and cash-burn sensitivities [#10Qp12].
2026-03-31catalystFurther dilution or financingHigh impact
High cash burn increases likelihood of near-term equity raises or debt that dilute holders or depresses equity value if on unfavorable terms [#10Qp34].
2026-12-31catalystCommercial adoption of sequencing servicesHigh impact
Growth in clinical/biopharma sequencing contracts could sustainably raise revenue trajectory if Personalis converts pilot programs to recurring revenue [#PR-2025-06-10].
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-26 • Updated nightlySource: Internal modelMethodology